Zetia, Ezetimibe Newswire

Zetia, Ezetimibe Newswire

Comprehensive Real-Time News Feed for Zetia, Ezetimibe (generic).

Results 1 - 20 of 105 in Zetia, Ezetimibe (generic)

  1. Esperion Therapeutics' (ESPR) Neutral Rating Reiterated at Chardan CapitalRead the original story w/Photo

    Friday Dec 8 | IntersportsWire

    The firm currently has a $75.00 price target on the biopharmaceutical company's stock, up from their previous price target of $20.00. "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe fixed dose combo has been confirmed by the FDA.

    Comment?

  2. CJEU holds that SPCs cannot be obtained on the basis of an ...Read the original story w/Photo

    Thursday Dec 7 | IPKat

    Back in July last year right, at the end of the Court's Trinity Term, Mr Justice Arnold referred two questions to the CJEU on the SPC Regulation in Merck Sharp & Dohme v Comptroller-General of Patents [2016] EWHC 1896 . Today, the Court of Justice of the European Union responded to Arnold J's questions in Case C-567/16 holding that an end of procedure notice does not amount to a granted marketing authorization for purposes of Article 3 .

    Comment?

  3. Chardan Capital Reiterates Neutral Rating for Esperion TherapeuticsRead the original story w/Photo

    Thursday Dec 7 | The Breeze

    's stock had its "neutral" rating reaffirmed by research analysts at Chardan Capital in a research report issued on Tuesday. They currently have a $75.00 price objective on the biopharmaceutical company's stock, up from their prior price objective of $20.00.

    Comment?

  4. Esperion Therapeutics' (ESPR) Hold Rating Reiterated at Chardan CapitalRead the original story w/Photo

    Tuesday Dec 5 | AmericanBankingNews.com

    The analysts wrote, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe fixed dose combo has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA.

    Comment?

  5. 3 Stocks That QuadrupledRead the original story w/Photo

    Monday Dec 4 | Fox News

    The stock market continues to put on a clinic about how to stomp all over expectations. The Dow Jones Industrial Average is up 25% this year and the S&P 500 is 20% higher, but stack them up next to Nektar Therapeutics Let's look more closely at these three biotechs to see whether there's any more room to run after quadrupling so far in 2017.

    Comment?

  6. Ezetimibe Increases Endogenous Cholesterol Excretion in HumansRead the original story w/Photo

    May 1, 2017 | Circulation

    From the Division of Endocrinology, Metabolism & Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO ; Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO ; and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO . From the Division of Endocrinology, Metabolism & Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO ; Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO ; and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO .

    Comment?

  7. Still a reasonable goal: Targeting cholesterol in dialysis and...Read the original story

    Tuesday Nov 28 | CiteULike

    Chronic kidney disease patients have a high burden of cardiovascular disease. In the general population, lipid metabolism disorders, which cause the initiation and progression of atherosclerotic vascular changes, are major targets for preventive and therapeutic strategies in cardiovascular medicine.

    Comment?

  8. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.Read the original story

    Monday Nov 20 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Markers of inflammation, including plasma C-reactive protein , are associated with an increased risk of cardiovascular disease, and it has been suggested that this association is causal.

    Comment?

  9. Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare ConferenceRead the original story w/Photo

    Monday Nov 13 | GlobeNewswire

    Esperion Therapeutics, Inc. , the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat with investors at the Jefferies 2017 London Healthcare Conference in London on Thursday, November 16, 2017 at 1:20 p.m. Greenwich Mean Time / 8:20 a.m. Eastern Time.

    Comment?

  10. Gemphire Therapeutics Presents Data at American Heart Association...Read the original story w/Photo

    Monday Nov 13 | GlobeNewswire

    Gemphire Therapeutics Presents Data at American Heart Association Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results LIVONIA, Mich., Nov. 13, 2017 -- Gemphire Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced the presentation of pre-clinical and clinical study results, its financial results for the three and nine month periods ended September 30, 2017, and provided a corporate update.

    Comment?

  11. Effect of statins and non-statin LDL-lowering medications on...Read the original story

    Nov 9, 2017 | CiteULike

    Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  12. Merck - Appeal Lures Driven By Keytruda As The 'Core' StrugglesRead the original story w/Photo

    Oct 30, 2017 | Seeking Alpha

    Merck & Co provided a nasty surprise for investors, despite the pick-up in sales of wonder drug Keytruda. The company saw sales of all other drugs fall quite a bit, as Keytruda will not be submitted for NSCLC in Europe.

    Comment?

  13. Merck swings to 3Q loss on big charge but raises forecastRead the original story w/Photo

    Oct 27, 2017 | Daily Journal

    Lower sales for multiple medicines and a whopping charge for a big cancer drug collaboration drove Merck & Co. to a third-quarter loss of $56 million, but it still beat the muted expectations of Wall Street.

    Comment?

  14. UPDATE 2-Merck profit beat clouded by NotPetya attack, shares dipRead the original story w/Photo

    Oct 27, 2017 | Reuters

    The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016. REUTERS/Mike Blake/Illustration/File Photo Sales of Keytruda more than doubled to $1.05 billion in the third quarter, but were not enough to boost Merck's total revenue, which fell about 2 percent to $10.33 billion.

    Comment?

  15. Esperion To Host Analyst And Investor Day Event On October 17Read the original story

    Oct 9, 2017 | BioSpace

    Esperion Therapeutics, Inc. , the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today announced it will host its third analyst and investor day event for institutional investors and research analysts in New York City on Tuesday, October 17 from 8:30 a.m. until 12:00 p.m. Eastern Time. The agenda features presentations from external investigators and independent advisors, along with members of the Esperion Lipid Management Team.

    Comment?

  16. Contrasting Esperion Therapeutics (ESPR) & Its PeersRead the original story

    Oct 7, 2017 | IntersportsWire

    Esperion Therapeutics is one of 196 public companies in the "Biotechnology & Medical Research" industry, but how does it weigh in compared to its rivals? We will compare Esperion Therapeutics to related companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership. 83.3% of Esperion Therapeutics shares are owned by institutional investors.

    Comment?

  17. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein...Read the original story

    Oct 6, 2017 | CiteULike

    Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals.

    Comment?

  18. Esperion Therapeutics (ESPR) vs. Its Rivals Head to Head ReviewRead the original story w/Photo

    Oct 5, 2017 | The Breeze

    Esperion Therapeutics is one of 196 public companies in the "Biotechnology & Medical Research" industry, but how does it compare to its competitors? We will compare Esperion Therapeutics to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations. Esperion Therapeutics has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500.

    Comment?

  19. Comparing Global Blood TherapeuticsRead the original story w/Photo

    Oct 3, 2017 | Daily Political

    Global Blood Therapeutics and Esperion Therapeutics are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation. 86.1% of Global Blood Therapeutics shares are owned by institutional investors.

    Comment?

  20. Critical Comparison: Esperion Therapeutics (ESPR) and Its PeersRead the original story w/Photo

    Oct 2, 2017 | Daily Political

    Esperion Therapeutics is one of 196 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it compare to its competitors? We will compare Esperion Therapeutics to similar companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability. Esperion Therapeutics has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500.

    Comment?